Home・Aandelen Lijst・Medpace Holdings Inc

Medpace Holdings Inc

Gesloten

SectorGezondheidszorg

583.47 -0.28

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

575.11

Max

589.66

Belangrijke statistieken
By Trading Economics
Inkomsten	-2.5M 121M
Verkoop	727K 707M
K/W Sectorgemiddelde	33.683 68.51
EPS	4.25
Winstmarge	17.158
Werknemers	6,500
EBITDA	-21M 134M

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	+0.89% upside

Dividenden
By Acuity
Volgende Winsten	21 okt 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	924M 16B
Vorige openingsprijs	583.75
Vorige sluitingsprijs	583.47

Medpace Holdings Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 aug 2026, 19:26 UTC

Medpace Holdings Inc shares are higher, tracking broader market gains as major technology stocks boost investor confidence amid declining energy prices.

30 jul 2026, 19:22 UTC

Medpace Holdings Inc is trading lower amid significant declines in the Life Sciences Tools & Services sub-sector, with unusual volatility noted during Thursday's session.

29 jul 2026, 18:44 UTC

Macro Event

Medpace Holdings Inc. is trading higher, buoyed by the Federal Reserve's steady interest rates, despite broader market pressures from rising oil prices and geopolitical tensions.

28 jul 2026, 23:11 UTC

Medpace Holdings Inc shares are higher in after-market hours, rebounding after four consecutive lower closes and remaining above the 20-day moving average.

27 jul 2026, 16:56 UTC

News

Medpace Holdings Inc. shares are lower amid broader market volatility, despite reporting strong Q2 2026 business awards and raising guidance.

24 jul 2026, 18:26 UTC

News

Analyst upgrades from RBC Capital and Truist Securities boost Medpace Holdings' price targets, contributing to modest gains during Friday's trading session.

22 jul 2026, 23:22 UTC

Social Media

News

Medpace Holdings Inc. reported Q2 revenue of $707.3 million, exceeding expectations, and raised 2026 guidance, driving shares higher in after-market trading.

21 jul 2026, 19:46 UTC

News

Medpace Holdings Inc. shares rise as analysts project 14.3% revenue growth ahead of Wednesday's Q2 earnings report, following a $706.6 million revenue last year.

Peer Vergelijking

Prijswijziging

Medpace Holdings Inc Prognose

Koersdoel

By TipRanks

0.89% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 580.2 USD 0.89%

Hoogste 692 USD

Laagste 450 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Medpace Holdings Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan Medpace Holdings Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Medpace Holdings Inc

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.